Work

DI-Leu16-IL2, an Anti-CD20-Interleukin-2 Immunocytokine, Is Safe and Active in Patients with Relapsed and Refractory B-Cell Lymphoma: A Report of Maximum Tolerated Dose, Optimal Biologic Dose, and Recommended Phase 2 Dose

Year: 2016

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v128.22.620.620

Authors: Frederick Lansigan, Ryotaro Nakamura, Donald P. Quick, Daniel Vlock, Andrew Raubitschek, Stephen D. Gillies, Veronika Bachanova

Institutions: Dartmouth–Hitchcock Medical Center, Dartmouth Cancer Center, City Of Hope National Medical Center, City of Hope, University of Minnesota Medical Center

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2736149368

FWCI: 1.046

Cites:

Cited by: 19

Related to: 10